Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01525238 · ClinicalTrials.gov registry record · Phase 1
PK Study of Dapagliflozin in Pediatric Subjects With T2DM
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 53
- Enrollment target
NCT01525238 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 53 participants.
The verdict
NCT01525238, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 53 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
Interventions
- DRUG Dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2012-07-01 |
| Est. Completion | 2014-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01525238
The ClinicalTrials.gov registry entry for NCT01525238 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dapagliflozin is the first listed.
NCT01525238 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01525238 about?
NCT01525238 is a clinical study titled "PK Study of Dapagliflozin in Pediatric Subjects With T2DM". The primary purpose of this study is to evaluate the pharmacokinetics (PK) of Dapagliflozin in pediatric subjects with type 2 diabetes mellitus (T2DM)
What is the current status of trial NCT01525238?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 53 participants. The study started on 2012-07-01. Estimated completion is 2014-09-01.
What interventions are being tested in trial NCT01525238?
The interventions under investigation include: Dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT01525238?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.